Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages

  Tan, Daniel S W ^a   Montoya, Joey ^a   Ng, Quan Sing ^a   Chan, Kian Sing ^b   Oon, Lynette ^b   Krisna, Sai Sakktee ^a   Takano, Angela ^b   Lim, Wan Teck ^a   Tan, Eng Huat ^a   Lim, Kiat Hon ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; GUANINE; K RAS PROTEIN; LEUCINE; PROTEIN P63; THYMINE; ANTINEOPLASTIC AGENT; ARGININE; DEOXYCYTIDINE; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; ELECTROPHORESIS; EXCISION; EXON; FATIGUE; FINE NEEDLE ASPIRATION BIOPSY; GENE SEQUENCE; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; MALE; MEDIASTINUM DISEASE; MOLECULAR GENETICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTANT; ONCOGENE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMOKING; SOMATIC MUTATION; SWELLING; WEIGHT REDUCTION; BIOPSY; CANCER STAGING; CARCINOMA; DISEASE FREE SURVIVAL; GENETICS; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; POINT MUTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGININE; BIOPSY; CARBOPLATIN; CARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCINE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; POINT MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

MLCS; MLOWN;

EID: 84879488821     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.3937     Document Type: Article

References (27)

1. Pavlidis N, Briasoulis E, Pentheroudakis G, et al: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v228-v231, 2010 (suppl 5)
2. Oien KA: Pathologic evaluation of unknown primary cancer. Semin Oncol 36:8-37, 2009
3. Greco FA, Hainsworth JD: Introduction: Unknown primary cancer. Semin Oncol 36:6-7, 2009
4. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al: Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27:2503-2508, 2009
5. Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462-469, 2008
6. Varadhachary GR, Spector Y, Abbruzzese JL, et al: Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17:4063-4070, 2011
7. Greco FA, Spigel DR, Yardley DA, et al: Molecular profiling in unknown primary cancer: Accuracy of tissue of origin prediction. The Oncologist 15:500-506, 2010
8. Hainsworth J, Spigel D: Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial. J Clin Oncol 28, 2010 (abstr 10540)
9. Tan D, Thomas G, Garrett M, et al: Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer 15:406-420, 2009
10. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180, 2011
11. Bollag G, Hirth P, Tsai J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599, 2010
12. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
13. Teng Y, Tan WJ, Thike AA, et al: Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy. Breast Cancer Res 13:R35, 2011
14. Kwak EL, Jankowski J, Thayer SP, et al: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287, 2006
15. Masago K, Asato R, Fujita S, et al: Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 124:2744-2749, 2009
16. Masago K, Miura M, Toyama Y, et al: Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. J Clin Oncol 29:e465-e467, 2011
17. Ricarte-Filho JC, Ryder M, Chitale DA, et al: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893, 2009
18. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
19. Deng N, Goh LK, Wang H, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684, 2012
20. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
21. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol (suppl) 28, 2010:abstract 3534
22. MacConaill LE, Campbell CD, Kehoe SM, et al: Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4:e7887, 2009
23. Santini D, Spoto C, Loupakis F, et al: High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice. Ann Oncol 21:1565, 2010
24. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 482:100-103, 2012
25. Navin N, Kendall J, Troge J, et al: Tumour evolution inferred by single-cell sequencing. Nature 472:90-94, 2011
26. Tan DS, Gerlinger M, Teh BT, et al: Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 46:2166-2177, 2010
27. MacConaill LE, Garraway LA: Clinical implications of the cancer genome. J Clin Oncol 28:5219-5228, 2010